Erschienen in:
01.07.2005 | Letter to the Editor
Epstein–Barr virus reactivation after allogeneic stem cell transplantation without lymph node enlargement
verfasst von:
William H. Krüger, Frank Schüler, Christian Lotze, Günther Schwesinger, Renate Mentel, Christoph Busemann, Gottfried Dölken
Erschienen in:
Annals of Hematology
|
Ausgabe 7/2005
Einloggen, um Zugang zu erhalten
Excerpt
Epstein–Barr virus-associated disease is a rare complication after allogeneic bone marrow transplantation (BMT) with a cumulative incidence of 1% at 10 years using nonmanipulated grafts [
1]. T-cell depletion increases the incidence significantly [
2]. Most cases occur during the 1st year after transplantation with the incidence highest at 2–3 months after BMT [
3]. Epstein–Barr virus (EBV) disease after stem cell transplantation is always a reactivation of latent infection and mainly derives from donor B lymphocytes. It presents usually as a disseminated disease with fever, lymph node enlargement, respiratory disease, and features of hepatitis [
1,
3,
4]. The common lymphadenopathy usually leads to diagnosis; however, cases diagnosed only at autopsy have been published [
5,
6]. …
